Skip to main content
. 2017 Jun 18;2017(6):CD004637. doi: 10.1002/14651858.CD004637.pub2

Boodt 1990.

Methods Design: randomised double‐blinded
No. eligible: not stated
No. randomised: 406
No. analysed: 406 (reported in table of results)
Drop‐outs/withdrawals: states 7 participants not evaluable (5 underwent vaginal hysterectomy with repair, 2 underwent surgery for urinary incontinence)
Years of recruitment: not stated
Setting: single centre, Dutch teaching hospital
Participants Inclusion criteria: patients hospitalised for an abdominal or vaginal hysterectomy or a vaginal hysterectomy with vaginal repair, who were informed about the objective of trial in writing before the operation and gave permission to be included
Exclusion criteria: emergency operation, known sensitivity to cephalosporins, preexisting infection or antibiotic therapy in the 48 hours preceding surgery
Age: 41 to 59 years
Type of hysterectomy: abdominal or vaginal (some vaginal with associated procedures).
Interventions Treatment: 1500 mg cefuroxime (second‐generation cephalosporin) plus 500 mg metronidazole (antiprotozoal)
Control: placebo
Route: IV
Single/multiple doses: single
Timing of doses: 10‐minute infusion during induction of anaesthesia
Outcomes Urinary tract infection
Pelvic infection
Postoperative fever
Need for therapeutic antibiotics
Length of hospital stay
Follow up: 6 weeks
Funding Not stated
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Stated as randomised but method not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection bias) 
 All outcomes Low risk "In view of the double blind...both the active and the placebo infusions were coloured yellow..."
Incomplete outcome data (attrition bias) 
 All outcomes Unclear risk Insufficient information on withdrawals and reasons for withdrawals
Selective reporting (reporting bias) Unclear risk Adverse effects not systematically reported
Other bias Low risk Baseline demographic characteristics similar between treatment groups